DK1446380T3 - Formoteroltartrafremgangsmåde og polymorf - Google Patents

Formoteroltartrafremgangsmåde og polymorf

Info

Publication number
DK1446380T3
DK1446380T3 DK02786502T DK02786502T DK1446380T3 DK 1446380 T3 DK1446380 T3 DK 1446380T3 DK 02786502 T DK02786502 T DK 02786502T DK 02786502 T DK02786502 T DK 02786502T DK 1446380 T3 DK1446380 T3 DK 1446380T3
Authority
DK
Denmark
Prior art keywords
polymorph
formoterol
tartar
procedure
tartrate
Prior art date
Application number
DK02786502T
Other languages
Danish (da)
English (en)
Inventor
Gerald J Tanoury
Chris H Senanayake
Donald W Kessler
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21892899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1446380(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of DK1446380T3 publication Critical patent/DK1446380T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK02786502T 2001-11-09 2002-10-23 Formoteroltartrafremgangsmåde og polymorf DK1446380T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/037,183 US6472563B1 (en) 2001-11-09 2001-11-09 Formoterol tartrate process and polymorph
PCT/US2002/034118 WO2003042165A1 (en) 2001-11-09 2002-10-23 Formoterol tartrate process and polymorph

Publications (1)

Publication Number Publication Date
DK1446380T3 true DK1446380T3 (da) 2010-01-04

Family

ID=21892899

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02786502T DK1446380T3 (da) 2001-11-09 2002-10-23 Formoteroltartrafremgangsmåde og polymorf

Country Status (13)

Country Link
US (10) US6472563B1 (enExample)
EP (3) EP2165999A1 (enExample)
JP (1) JP4271574B2 (enExample)
AT (1) ATE450497T1 (enExample)
AU (2) AU2002349914B2 (enExample)
CA (1) CA2477642C (enExample)
CY (1) CY1109832T1 (enExample)
DE (1) DE60234629D1 (enExample)
DK (1) DK1446380T3 (enExample)
ES (2) ES2336436T3 (enExample)
PT (1) PT1446380E (enExample)
SI (1) SI1446380T1 (enExample)
WO (1) WO2003042165A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472563B1 (en) * 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
WO2005019227A1 (en) * 2003-08-22 2005-03-03 Orchid Chemicals & Pharmaceuticals Ltd Process for the preparation of cephalosporin antibiotic
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20060160841A1 (en) * 2005-01-19 2006-07-20 Chenkou Wei Crystallization via high-shear transformation
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718822B2 (en) * 2007-08-28 2010-05-18 Sepracor Inc. Carbamate Stereoisomer
US8501994B2 (en) * 2007-08-28 2013-08-06 Sunovion Pharmaceuticals Inc. Acetamide stereoisomer
CN101393186A (zh) * 2007-09-21 2009-03-25 北京德众万全药物技术开发有限公司 一种hplc法分离分析酒石酸福莫特罗手性异构体的方法
US20090215734A1 (en) * 2008-02-26 2009-08-27 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) * 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2262479A2 (en) * 2008-02-28 2010-12-22 Actavis Group PTC ehf. Amorphous arformoterol l-(+)-tartrate
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
WO2010128355A2 (en) 2008-12-26 2010-11-11 Actavis Group Ptc Ehf Improved processes for preparing substantially pure arformoterol and its intermediates
WO2011038872A1 (en) * 2009-10-02 2011-04-07 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate
IT1399912B1 (it) * 2010-04-29 2013-05-09 Lundbeck Pharmaceuticals Italy S Pa Processo di preparazione di ritodrina cloridrato.
ME02153B (me) 2011-09-19 2015-10-20 Orexo Ab Nove farmaceutske kompozicije, otporne na zloupotrebu, za tretman zavisnosti od opioida
CN104220420B (zh) * 2012-03-12 2016-08-31 利斯维实验室有限公司 一种长效β-2肾上腺素受体激动剂的新型多晶
NZ710740A (en) 2013-02-28 2020-06-26 Dermira Inc Glycopyrrolate salts
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
JP2016523832A (ja) * 2013-05-17 2016-08-12 グレンマーク・ファーマシューティカルズ・リミテッド アルホルモテロールまたはその塩の調製のためのプロセス
CN107151219A (zh) * 2017-05-23 2017-09-12 北京万全德众医药生物技术有限公司 酒石酸阿福特罗的精制方法
CN111909049B (zh) * 2020-09-03 2023-04-25 扬州中宝药业股份有限公司 一种酒石酸阿福特罗精制的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2005492A6 (es) 1987-12-23 1989-03-01 Lasa Lab Procedimiento de obtencion de n-(2-hidroxi-5-(1-hidroxi-2((2- (4-metoxifenil)-1metiletil)amino)etil)fenil)foramida (i).
ES2031407A6 (es) 1988-10-05 1992-12-01 Lasa Lab Mejoras introducidas en el objeto de la patente principal n{ 8703715 por: procedimiento de obtencion de n-(2-hidroxi-5-(1-hidroxi-2-((2-(4-metoxifenil)-1-metiletil)amino)etil)fenil)formamida".
SE8901060D0 (sv) 1989-03-28 1989-03-28 Draco Ab New compounds
US5434304A (en) * 1990-09-26 1995-07-18 Aktiebolaget Astra Process for preparing formoterol and related compounds
SE9003057D0 (sv) 1990-09-26 1990-09-26 Astra Ab New process
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
ATE234604T1 (de) * 1998-08-04 2003-04-15 Jago Res Ag Medizinische aerosolformulierungen
US6472563B1 (en) * 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph

Also Published As

Publication number Publication date
US20050148667A1 (en) 2005-07-07
WO2003042165A1 (en) 2003-05-22
CY1109832T1 (el) 2014-09-10
CA2477642C (en) 2014-02-11
US20030149304A1 (en) 2003-08-07
US20060264507A1 (en) 2006-11-23
US20040176450A1 (en) 2004-09-09
AU2002349914B2 (en) 2008-09-04
US6720453B2 (en) 2004-04-13
ES2685100T3 (es) 2018-10-05
AU2008253696A1 (en) 2009-01-08
US6472563B1 (en) 2002-10-29
SI1446380T1 (sl) 2010-03-31
US7732641B2 (en) 2010-06-08
US20090156862A1 (en) 2009-06-18
US7342132B2 (en) 2008-03-11
US20120108670A1 (en) 2012-05-03
CA2477642A1 (en) 2003-05-22
EP1446380B1 (en) 2009-12-02
EP1446380A1 (en) 2004-08-18
EP2165999A1 (en) 2010-03-24
US20100249459A1 (en) 2010-09-30
US20100204336A1 (en) 2010-08-12
EP2305635A3 (en) 2011-07-20
EP2305635B1 (en) 2018-06-13
DE60234629D1 (de) 2010-01-14
US7145036B2 (en) 2006-12-05
US20080114187A1 (en) 2008-05-15
PT1446380E (pt) 2010-01-07
EP2305635A2 (en) 2011-04-06
ES2336436T3 (es) 2010-04-13
US7479572B2 (en) 2009-01-20
ATE450497T1 (de) 2009-12-15
US8110706B2 (en) 2012-02-07
US7964753B2 (en) 2011-06-21
AU2008253696B2 (en) 2012-04-12
JP2005509025A (ja) 2005-04-07
JP4271574B2 (ja) 2009-06-03

Similar Documents

Publication Publication Date Title
CY1109832T1 (el) Επεξεργασια τρυγικης φορμοτερολης και πολυμορφο
WO2000021487A3 (en) Formoterol polymorphs
LU92520I2 (fr) Bédaquiline, ou son sel d'addition d'acide ou de base pharmaceutiquement acceptable, y compris le fumarate de bédaquiline
NO20012921L (no) Fenylglycin-derivater
DK1513516T3 (da) Substitueret 3-amino-thieno(2,3-b)-pyridin-2-carboxylsyreamid-forbindelser og fremgangsmåder til fremstilling og deres anvendelser
IS6859A (is) Kristölluð form atorvastatíns
TW200716520A (en) 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
MXPA05003093A (es) Diaril eteres como antagonistas de receptor opiode.
NO20040794L (no) (-)-1-(3,4-Diklorfenyl)-3-azabicyklo[3.1.0]heksan, forbindelser derav og anvendelser som en dopamin-gjenopptaks-inhibitor.
NO329883B1 (no) Fremgangsmate for fremstilling av prostaglandiner og analoger derav og av mellomforbindelser, og forbindelser fremstilt derved
NO20044442L (no) Fosfatprodroger av fluoroksindoler
CY1108808T1 (el) Ενωσεις μοτιλιδης
HUP0303639A2 (hu) Új amlodipin-kamzilát és eljárás annak előállítására
NO20040881L (no) Orale antidiabetes midler.
EA200301276A1 (ru) Новые производные сульфоновых кислот
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
RU2002130710A (ru) Производное пиридин-1-оксида и способ его преобразования в фармацевтически эффективные соединения
NO20040388L (no) Fremgangsmåte for fremstilling av beraprost og salter derav, samt forbindelser som er mellomprodukter i fremgangsmåten
IS7289A (is) Kristallaður venlafaxínbasi og nýir fjölgervingarvenlafaxínhýdróklóríðs, aðferðir til að framleiðaþá
NO20042681L (no) Ny krystallinsk polymorf av venlafaxine-hydroklorid og fremgangsmater for fremstilling derav
NO995676L (no) Isoftalamid derivat som gul polymorf
EE200200583A (et) (E)-N-(6,6-dimetüül-2-hepteen-4-ünüül)-N-metüül-1-naftaleenmetaanamiini (terbinafiin) valmistamise meetod
ZA200300218B (en) Novel N-(2-phenyl-3-aminopropyl)naphtamides.
NO20043047L (no) Mellomprodukter for LHRH-antagonistsyntese, fremgangsmate for fremstilling derav og fremgangsmate for LHRH-antagonistfremstilling
WO2002053537A8 (en) Process for preparing (±) trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine